Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection – Network Sites and Coordinating Center (U01- CT Not Allowed)
ID: 360432Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360432
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a funding opportunity for the Stroke Preclinical Assessment Network (SPAN) to support translational studies focused on acute cerebroprotection in experimental models of acute ischemic stroke. This initiative aims to establish a collaborative network comprising a Coordinating Center and up to six peer-reviewed data collection sites, emphasizing rigorous methodologies and replication in preclinical testing of stroke treatments. The estimated total program funding is $500,000, with one award expected to be made, and interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published by December 2025. For further inquiries, potential applicants can contact Francesca Bosetti at 301-496-1297 or via email at frances@mail.nih.gov.

    Point(s) of Contact
    Francesca Bosetti
    (301) 496-1297
    frances@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the NIH StrokeNet Clinical Trials and Biomarker Studies aimed at enhancing stroke treatment, recovery, and prevention strategies. This initiative invites applications for multi-site exploratory and confirmatory clinical trials, as well as biomarker validation studies and ancillary studies linked to ongoing StrokeNet projects, with a focus on innovative interventions and patient-centric designs. The funding is structured as a cooperative agreement (UG3/UH3), allowing for initial support of one year with the potential for six additional years based on milestone achievements. Interested applicants, including academic institutions, nonprofits, and government agencies, must adhere to specific submission guidelines and deadlines, with applications due by November 19, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-052.html.
    NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)." This initiative aims to support multi-site exploratory and confirmatory clinical trials that focus on innovative interventions, biomarker validation, and ancillary studies related to stroke prevention, treatment, and recovery. The program emphasizes collaboration within the NIH StrokeNet infrastructure to enhance patient recruitment and trial execution, addressing critical public health issues associated with stroke. Interested applicants must submit their proposals by November 19, 2026, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States," aimed at advancing research on the relationship between stroke events and cognitive impairment in post-stroke populations. This initiative seeks to explore the clinical factors that may contribute to dementia outcomes in individuals who have experienced strokes, addressing a significant public health concern given that one in three people will have a stroke in their lifetime, with dementia affecting approximately 30% of post-stroke patients. The total estimated funding for this program is $10 million, with one award expected to be granted, and interested applicants who have previously received funding under RFA-NS-19-012 are encouraged to prepare their proposals ahead of the anticipated application period, which is expected to open on October 28, 2025, with a closing date of November 28, 2025. For further inquiries, potential applicants can contact Dr. Lina Garcia at lina.garcia@nih.gov or by phone at 301-496-9135.
    Forecast for The NINDS Human Biospecimen and Data Repository (U24 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the NINDS Human Biospecimen and Data Repository, aimed at advancing research in neurological disorders. This initiative will establish a repository to maintain and expand a collection of biospecimens, which will be made available to qualified academic and industry researchers to support basic, translational, and clinical research efforts. The total estimated funding for this program is $1,950,000, with one award anticipated, and interested applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on August 25, 2025. For further inquiries, potential applicants can contact Dr. Rebecca Price at rebecca.price@nih.gov or by phone at 301-827-3587.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at investigating novel therapeutic interventions and testing strategies for neurological disorders, specifically targeting the treatment, modification, and prevention of epilepsy. This initiative encourages applicants to explore various intervention modalities and develop human-focused testing approaches, with a particular emphasis on preclinical therapy testing and model development. The total estimated program funding is $6.2 million, with individual awards ranging from $3.5 million to $4 million, and the application process is expected to open with a synopsis posted by December 19, 2025, closing on February 20, 2026. Interested applicants can reach out to Dr. Brian Klein at brian.klein@nih.gov or (301) 496-0981 for further information.
    NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), aimed at supporting multi-center clinical trials focused on neurological emergencies such as status epilepticus and traumatic brain injury. This initiative encourages collaboration with the NIH SIREN Clinical Coordinating Center to ensure efficient trial implementation, while applicants are expected to provide rigorous preclinical data and compelling rationales for their proposed interventions. The funding opportunity operates under a phased mechanism, with UG3 for planning and UH3 for execution, reflecting a commitment to enhance clinical research in emergency care. Interested applicants can find more information and application guidelines at the provided link, with a submission deadline of March 6, 2026, and no cost-sharing or matching requirements.
    NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00), aimed at supporting graduate students from underrepresented backgrounds in completing their Ph.D. and transitioning to neuroscience postdoctoral positions. This initiative seeks to enhance diversity in the neuroscience workforce by providing a structured mentorship and career development pathway over a maximum of six years, with approximately 36 awards available annually totaling around $2 million. Interested applicants from eligible domestic institutions must adhere to specific application guidelines, as late submissions will not be accepted. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and the application deadline is set for October 6, 2026.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.